Chinese biopharmaceutical firm Adlai Nortye bags $100m in a Series D round
Photo: Pixabay
Hangzhou Adlai Nortye Biopharma Co., Ltd, a Chinese clinical-stage biopharmaceutical firm that makes immuno-oncology medicines, has raked in $100 million in a Series D round, according to a company statement on Tuesday.
Create an account to continue reading our free content.
Already have an account? Sign in here
Bring stories like this into your inbox every day.
Sign up for our newsletter – The Daily Brief
Related Stories
Adlai Nortye had closed $53 million in a Series B round led by YuanMing Capita in July 2018.
Shanghai-based healthcare PE fund C-Bridge Capital has led a $20 million Series B funding round into Nuance Biotech while YuanMing Capital leads $5
